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PrognosisAbstract Hypersensitivity pneumonitis (HP) is an immunologically induced lung disease caused by
inhalation of a variety of environmental agents. HP is not a uniform disease but rather a complex
syndrome characterized by varying intensities of responsiveness to different antigens leading to an
immunopathology with variable clinical presentation and natural history. We studied the associa-
tion between serum TNF-alpha and CD4/CD8 ratio with chest computed tomography findings and
steroid responsiveness.
Methods: The study included 46 patients with chronic hypersensitivity pneumonitis, 22 (47.8%)
male and 24 (52.8%) female. mean age 49 ± 8 years. All patients underwent high resolution chest
computed tomography, TNF-alpha ELIZA assay, and cd3, cd4, cd8, CD4/CD8 by flow cytometry.
Results: The TNF-alpha level was (mean ± SD) 299 ± 427 pg/ml, CD4/CD8 ratio (84 ± 36).
With regard to steroid responsiveness (26) 57% patients were steroid responders while 20 (43%)
were non-responders.
TNF-alpha level was significantly lower in patients with predominant ground glass in their chest
computed tomography (p= 0.014), however CD3, CD4, CD8, CD4/CD8 levels showed insignifi-
cant differences between patients with ground glass and those with fibrosis in their chest computed
tomography.
Finally, TNF-alpha level was significantly lower in patients with good steroid response
(p= 0.014), on the other hand CD4/CD8 ratio was significantly higher in those with good steroid
response (P= 0.011).
Conclusion: Low TNF-alpha and high CD4/CD8 ratio could be used as a predictor of steroid
responsiveness in CHP patients.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
690 A. Rashad et al.Introduction
Extrinsic allergic alveolitis (EAA) belongs to the family of
interstitial lung diseases. It results from repeated inhalation
of causative antigens in susceptible people. The prevalence of
the disease is unknown. It is probable that both humoral
and cellular mechanisms participate in the development of
the lung lesion after the repeated inhalation of offending anti-
gens. For the acute form of the disease, which occurs several
hours after the antigen challenge, an immune complex medi-
ated tissue injury is typical [1,2].
On the other hand, T cell mediated immune inflammatory
response prevails in advanced stages of the disease [3].
The clinical presentation of the disease has been defined as
acute, subacute, and chronic. According to recent knowledge,
the disease could be retrospectively classified as acute intermit-
tent, acute progressive, chronic progressive, and chronic non-
progressive [4].
Exposure to known sensitizing antigens is the most impor-
tant diagnostic sign [4]. The typical high resolution computed
tomography (HRCT) findings, bronchoalveolar lavage (BAL),
and in some cases the surgical lung biopsy are also important
for diagnosis of EAA [5].
Hypersensitivity pneumonitis (HP) is an immunologically
induced lung disease caused by inhalation of a variety of
environmental agents [6]. HP is not a uniform disease but
rather a complex syndrome characterized by varying intensities
of responsiveness to different antigens leading to an
immunopathology with variable clinical presentation and nat-
ural history [7]. The long-term outcome of bird fancier’s lung
and farmer’s lung appears to be variable, including persistent
obstructive airways disease [8–10]. Continued exposure to anti-
gen does not consistently lead to clinical deterioration, except
in some patients such as those with pigeon breeder’s disease.
Patients with pigeon breeder’s disease and farmer’s lung fre-
quently progress to pulmonary fibrosis despite avoidance of
exposure to pigeon antigens [8,9,11]. Development of pul-
monary fibrosis appears to depend on the immune responses
of individual patients and/or the biologic characteristics of
the causative antigen. Bronchoalveolar lavage (BAL) has
revealed many characteristic aspects of cellular and humeral
components of HP. It is widely accepted that predominant
CD8 + T lymphocyte alveolitis is a feature of HP at an acute
phase. However, in several cases, especially at a chronic phase,
pulmonary fibrosis may be another feature of radiologic find-
ings of HP, and CD8 + T-cell dominance in BAL fluids may
disappear [12,13].
Tumor necrosis factor (TNF)-a is produced primarily by
activated macrophages [14,15]. It is viewed as a pleiotropic
cytokine with broad immune regulation functions and is closely
related to the development of diseases [16,17] TNF-a exerts its
diverse biological effects by binding to two specific cell surface
receptors (membrane TNF receptor [mTNFR]-1 and mTNFR-
2) [18,19], which are expressed on a variety of cells [19–21].
Both receptors can be shed from the cell surface to form soluble
TNF receptor (sTNFR)-1 and sTNFR-2 [20–25].
Patients
A single center observational study was carried out in the chest
department, Assuit University hospital, Assuit Egypt (Tertiaryhospital for all upper Egypt Governorates) between January
2013 and December 2014. The study included 46 patients, 22
(47.8%) male and 24 (52.8%) female.
All patients with chronic hypersensitivity pneumonitis
(CHP), admitted during the study period to Chest department
at Assuit University, who agreed to participate in the research,
were included in this study. The diagnosis of CHP was made
based on history of exposure, clinical examination, high-
resolution computerized tomography (HRCT) of the chest
and pulmonary function testing (PFT). None of the cases
accepted to confirm the diagnosis by either thoracoscopic lung
biopsy or transbronchial lung biopsy. The presence of typical
clinical and HRCT features of CHP, when identified by expert
clinicians and radiologists, is sufficiently characteristic to allow
a confident diagnosis and eliminate the need for surgical lung
biopsy. All cases had also abnormal pulmonary function stud-
ies including evidence of restriction—reduced vital capacity
with increased FEV1/FVC ratio. There was no evidence of
either coexisting collagen-vascular disease.
Steroid responsiveness was assessed according to clinical,
radiographic, and physiologic scoring system for the longitudi-
nal assessment of patients with idiopathic pulmonary fibrosis
[26,27].
The study was approved by the Re-search Ethics Commit-
tee Assuit Faculty of Medicine, Assuit university.
Methodology
Sample collection and laboratory investigations
A 5-ml sample of venous blood was collected from both
patient and control groups by venipuncture under completely
aseptic conditions. The samples were collected in two types
of tubes:
1. 3 ml of venous blood in plain tubes and were allowed to
clot at room temperature for at least 30 min, then cen-
trifuged at 1500 rpm for 15 min at room temperature to
get serum samples. Serum samples were divided and stored
in aliquots at 20 C until analyzed.
2. 2 ml of venous blood in K3EDTA anticoagulant tubes for
complete blood count (CBC) and Flowcytometic analysis.
Assay of serum levels of TNF-a was performed using
AviBion Human TNF-a ELISA Kit (Orgenium, Finland,
Rev 02.10) according to the manufacturer.
CBC for patients was done by Cell-Dyne 3700 Appott USA
according to the manufacturer and absolute lymphocytic count
was determined for patients.
Flowcytometry analysis
T- Lymphocyte subsets in whole blood samples were enumer-
ated using fluoroisothiocyanate (FITC)-conjugated CD 4
(Becto + Dickinson, Bioscience, USA), phycoerythrin (PE)
conjugated CD8 (Becton Dickinson, Bioscience, USA) and
peridinium-chlorophyll-protein (Per-CP)-conjugated CD3
(Becton Dickinson, Bioscience, USA). 100 ll of blood sample
was incubated with 20 ll of CD4, CD8, CD 3 triple color for
15 min at room temperature in the dark followed by incuba-
tion, RBC lysis, and washing with phosphate buffered saline






















Figure 3 Response to corticosteroid.
TNF-Alpha and CD4/CD8 ratio 691Flow cytometric analysis was done by FACS Calibur flow
cytometry with CellQuest software (Becton Dickinson
Biosciences, USA). An isotype-matched negative control was
used with each sample. Forward and side scatter histogram
was used to define the lymphocyte population (R1). % of
CD 3 positive cells refers to the total T Lymphocytes; CD 4
positive cells are the helper cells and CD8 positive are the
cytotoxic cells.
Radiologic assessment
HRCT images were obtained on a variety of scanners using
1- to 2-mm collimation with 10- to 20-mm spacing and a
high-spatial frequency reconstruction algorithm. An experi-
enced thoracic radiologist who was blinded to all clinical data
reviewed the CT scans. The radiologist assessed the scans for
the presence or absence of parenchymal fibrosis. Parenchymal
fibrosis was defined as the presence of irregular linear opaci-
ties, traction bronchiectasis, or honeycombing [27].
Results
The current study included 46 patients with CHP, 22 male and
24 female, mean age 49 ± 8 years. Two patients were current
smokers, 8 ex-smokers and 36 patients were non-smokers
(Table 1).
Ten (22%) patients were bird breeders, 8 patients (17%)
were employers, 12 (26%) farmers and 16 (35%) housewives
(Fig. 1).
Chest computed tomography evaluation of 46 patients with
CHP showed that 26 (56%) patients have more than 30%
areas of ground glass, as evaluated by two independent radiol-
ogist, while 20 (44%) of patients have less than 30% ground
glass, fibrosis or reticulonodular pattern was the predominant
feature in their chest computed tomography (Fig. 2).
The TNF-alpha level was (mean ± SD) 299 ± 427 pg/ml,
CD4/CD8 ratio (84 ± 36). With regard to steroid responsive-
ness 26 (57%) patients were steroid responders while 20 (43%)
were non-responders (Fig. 3).
TNF-alpha level was significantly lower in patients with
predominant ground glass in their chest computed tomogra-
phy (p= 0.014), however CD3, CD4, CD8, CD4/CD8 levels
showed insignificant differences between patients with ground
glass and those with fibrosis in their chest computed tomogra-
phy (Tables 2–4).
Finally, TNF-alpha level was significantly lower in patients
with good steroid response (p= 0.014), on the other hand
CD4/CD8 ratio was significantly higher in those with good
steroid response (P= 0.011).Table 1 Demographic data of study population.
Age (mean ± SD) 49 ± 8.7
Sex
Male (%) 22 (48)
Female (%) 24 (52)
Smoking status
Current smoker (%) 2 (4)
Ex-smoker (%) 8 (17)
Non-smoker (%) 36 (79)Discussion
In the current study we found that, TNF-alpha is negatively
associated with response to corticosteroid treatment in patients
with CHP, and it was associated with more fibrosis in chest
computed tomography of these patients. On the other hand
the CD4/CD8 ratio was more positively correlated with steroid
response in patients with CHP, also, ground glass pattern on
chest computed tomography was significantly correlated with
steroid response.
EAA is a disease characterized by pulmonary inflammation
and granuloma formation. Alveolar macrophage (AM) and
AM-derived cytokines, in particular TNF-alpha, play a crucial
Table 2 CD3, CD4, CD8, CD4/CD8 and TNF-alpha accord-
ing to chest computed tomography.
Fibrosis Ground glass P value
CD3 (Mean ± SD) 4 ± 4 5 ± 6 0.695
CD4 (Mean ± SD) 2 ± 2 2 ± 3 0.825
CD8 (Mean ± SD) 2 ± 2 3 ± 4 0.488
CD4/CD8 (Mean ± SD) 84 ± 42 84 ± 32 0.998
TNF-a (Mean ± SD) 540 ± 486 114 ± 267 0.014
Table 3 CD3, CD4, CD8, CD4/CD8 and TNF-alpha accord-






CD3 (Mean ± SD) 2.4 ± 1.5 5.5 ± 6.7 0.223
CD4 (Mean ± SD) 0.9 ± 0.7 2.5 ± 3 0.17
CD8 (Mean ± SD) 1.5 ± 1 3 ± 3.7 0.313
CD4/CD8 (Mean ± SD) 59 ± 15 98 ± 37 0.011
TNF-a (Mean ± SD) 540 ± 486 114 ± 267 0.014
Table 4 Steroid response according to chest computed
tomography.
CT-Chest
Steroid response Ground glass Fibrosis P-value
Responder (26) 20 6 0.04
Non-responder (20) 6 14
692 A. Rashad et al.role in these processes. TNF-alpha, spontaneously released by
activated AMs in EAA, can enhance the production of
interleukin-1, interleukin-6, monocyte-chemoattractant
protein-1, and macrophage inflammatory protein-1alpha
[16,17], all mediators that have been shown to be involved in
the development of EAA [28–31]. TNF-alpha can promote
cellular recruitment and activation in the lungs and thus
contribute to the alveolitis characterized by infiltration of
mononuclear cells and the formation of granulomas [28–30].
Previous studies have shown that the CD4/CD8 ratio in
BAL fluid may vary significantly according to the clinical pre-
sentation of the disease, the biological characteristics of the
inhalation antigen, the exposure to the causative antigen at
the time of the diagnosis, the immune susceptibility of partic-
ular patients, and to the history of smoking [32]. Our data sup-
port the hypothesis of the correlation of the continuous
exposure to the inhalation antigen and the low CD4/CD8 ratio
in BAL fluid. Murayama raises the possibility that increased
CD8 + T cells might have a protective effect against pul-
monary fibrosis while comparatively increased CD4 + T cells
might play an important part in the pathogenesis of pul-
monary fibrosis in EAA [33]. We proved that the persons with
the normal CD4/CD 8 ratio had higher interstitial scores.
Mornex et al.” reported that CD4 + cell-dominant T lym-
phocytosis was observed in BAL fluids of HP when the expo-
sure to antigens had been avoided for more than five days.
Although CD4 + cell-dominant T lymphocytosis of the fibro-
sis group is similar to those patients after the avoidance ofexposure, our observation regarding T cells in BAL fluids
was obtained during continuous exposure to the antigen.
The chronic stage of HP has been extensively characterized
in the farmer’s lung, [34] in which the principal findings were
interstitial pulmonary fibrosis and CD4 + T-cell dominance
in BAL fluids in several cases. In addition, the chronic stage
of bird fancier’s lung has been reported to develop pulmonary
fibrosis and have CD4 + T-cell-dominant BAL findings [35].Conflict of interest
The authors declare that they have no conflict of interest.References
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